SMARCA2 and small cell lung carcinoma: AU-15330 treatment resulted in time and dose-dependent degradation of mSWI/SNF ATPases (SMARCA2 and SMARCA4) and PBRM1 in cell lines encompassing all four molecular subtypes of SCLC (Fig. 1E, Fig. S1C).